Business Summary

Alkermes Public Limited Company is a fully integrated biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The Company's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.